Due to subsequent funding from the Central Bank of India, the company able to start their manufacturing facility for producing folic acid and iron tablets for the Indian government's mother and child health program.

[20] The Forbes list of India’s 100 richest tycoons, published in October 2024, ranks the Gupta family 52nd with a net worth of $5.75 Billion.

Other products in Lupin's branded portfolio include Antara< (Fenofibrate), Locoid lotion, Alinia (Nitazoxanide) and InspiraChambers (Anti-static valved holding chamber).

Lupin's focus in the European Union encompasses Anti-Infectives, Cardiovascular, and CNS therapy areas, along with niche opportunities in segments like Oral Contraceptives, Dermatology and Ophthalmics.

The company's presence in France is by way of a trade partnership; in Germany, it operates through its acquired entity Hormosan Pharma GmbH. ]

In 2014, Lupin entered into a strategic joint venture agreement with Toyama-based Japanese pharmaceuticals company, Yoshindo Inc. to create YL Biologics (YLB).

[33] YLB will be jointly managed by both partners and will be responsible for conducting clinical development of certain biosimilars including regulatory fillings and obtaining marketing authorization in Japan.

In 2019, Lupin exited the generic pharmaceuticals business in Japan by divesting its stake in Kyowa to private equity firm Unison for an enterprise value of Japanese 57,361 million yen (Rs 3,702.4 crore).

The company is also a strategic supplier of anti-TB products to the Stop TB Partnership, with its formulations supplied to more than 50 countries through GDF procurement.

Rgwduen is also a global leader in anti-TB APIs, and is associated with the Revised National Tuberculosis Control Program of the Government of India.

[citation needed] The Lupin Biotechnology Research Group, based out of Ghotawade & Wakad, near Pune is focussed on developing biosimilars.

Lupin has competencies for the complete development and manufacture of recombinant protein therapeutic products from high yielding and proprietary microbial and mammalian cell culture platforms.

The initiative has so far reached out to over 2.8 million people across over 3,400 villages in eight states of India including Rajasthan, Madhya Pradesh, Maharashtra, Uttarakhand, Gujarat and Goa.

[13] In July 2018, Lupin foundation signed a statement of Intent with the National Institution for Transforming India (Niti Aayog), a policy think tank of the government of India, to collaborate in the Aspirational Districts Programme and support the development of three backward districts – Nandurbar in Maharashtra, Vidisha in Madhya Pradesh and Dholpur in Rajasthan.